Latest revenue
$2.0M
as of 2026-03-31
Latest net income
$-19.8M
as of 2026-03-31
Net margin
-993.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ACRS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $609.6M
- Enterprise value
- $591.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 4.24×
- Dividend yield
- 0.0%
- 52-wk high
- $5.15
- 52-wk low
- $1.34
- Beta
- —
- Shares out
- 139.7M
5-year trend
What this company does
Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions, or the negative of such words or phrases, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and…
AI summary unavailable — showing raw filing excerpt
Generated from ACRS's filing dated 2015-11-18
Key risks
Item 1A. Risk Factors Our business is subject to numerous risks. You should carefully consider the following risks and all other information contained in this Annual Report, as well as general economic and business risks, together with any other documents we file with the SEC. If any of the following events actually occur or risks actually materialize, it could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline. Summary of Risk Factors ●We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain…
AI summary unavailable — showing raw filing excerpt
Generated from ACRS's filing dated 2015-11-18
Profitability
Operating margin
-975.9%
28.7%Net margin
-829.6%
17.6%Return on equity
-41.7%
50.3%Return on assets
-40.5%
32.5%Leverage
Debt / equity
0.03×
92.1%Debt / assets
3.1%
89.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.0M | +37.2% | $-19.8M | -31.4% | -993.2% |
Q4 2025 2025-12-31 | $1.3M | -85.9% | $-19.8M | +79.5% | -1528.6% |
Q3 2025 2025-09-30 | $3.3M | -24.1% | $-14.6M | -92.6% | -443.0% |
Q2 2025 2025-06-30 | $1.8M | -35.8% | $-15.4M | -40.4% | -868.3% |
Q1 2025 2025-03-31 | $1.5M | -39.3% | $-15.1M | +11.0% | -1036.8% |
Q4 2024 2024-12-31 | $9.2M | — | $-96.6M | — | -1048.3% |
Q3 2024 2024-09-30 | $4.3M | -53.2% | $-7.6M | +74.1% | -174.6% |
Q2 2024 2024-06-30 | $2.8M | +48.0% | $-11.0M | +62.8% | -397.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ACRS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.4M
Net activity
−$1.4M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACRS
Institutional value
$157.9M
Total shares held
43.8M
Distinct holders
68
-53 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 14.3M | $53.4M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 7.4M | $27.8M | +602.2K (+8.8%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5.2M | $19.4M | — | New |
| 4 | Decheng Capital LLC | 4.0M | $15.2M | +0 (+0.0%) | No change |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7M | $6.2M | — | New |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 1.4M | $5.3M | -15.8K (-1.1%) | Trimmed |
| 7 | DEUTSCHE BANK AG\ | 997.9K | $3.7M | +10.5K (+1.1%) | Added |
| 8 | Aldebaran Capital, LLC | 947.2K | $3.6M | -7.1K (-0.7%) | Trimmed |
| 9 | Three Bridge Wealth Advisors, LLC | 714.8K | $2.7M | +0 (+0.0%) | No change |
| 10 | VANGUARD FIDUCIARY TRUST CO | 628.9K | $2.4M | — | New |
| 11 | DIMENSIONAL FUND ADVISORS LP | 511.5K | $1.9M | +240.6K (+88.8%) | Added |
| 12 | Monashee Investment Management LLC | 500.0K | $1.9M | — | New |
| 13 | JPMORGAN CHASE & CO | 486.6K | $1.7M | -139.3K (-22.3%) | Trimmed |
| 14 | Aisling Capital Management LP | 434.5K | $1.6M | +0 (+0.0%) | No change |
| 15 | Russell Investments Group, Ltd. | 308.2K | $1.2M | +298.4K (+3049.4%) | Added |
| 16 | HighTower Advisors, LLC | 305.8K | $1.1M | -112 (-0.0%) | Trimmed |
| 17 | SEI INVESTMENTS CO | 217.2K | $814.3K | — | New |
| 18 | Invesco Ltd. | 214.9K | $806.0K | +5.0K (+2.4%) | Added |
| 19 | MACKENZIE FINANCIAL CORP | 213.4K | $800.3K | — | New |
| 20 | Bank of New York Mellon Corp | 207.0K | $776.3K | +3.5K (+1.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ACRS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.